Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,718 | -25,504 | -19,157 | -11,927 | -5,878 |
| Depreciation Amortization | 4 | 17 | 13 | 9 | 5 |
| Accounts payable and accrued liabilities | 486 | -127 | 755 | 250 | 424 |
| Other Working Capital | 192 | 448 | 1,934 | 1,916 | 756 |
| Other Operating Activity | 77 | 4,136 | 2,476 | 523 | -5 |
| Operating Cash Flow | $-5,959 | $-21,030 | $-13,979 | $-9,229 | $-4,698 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -19 | -19 | -9 | -6 |
| Investing Cash Flow | $-9 | $-19 | $-19 | $-9 | $-6 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 3,673 | 304 | 304 | 204 |
| Financing Cash Flow | $N/A | $3,673 | $304 | $304 | $204 |
| Beginning Cash Position | 71,194 | 88,570 | 88,570 | 88,570 | 88,570 |
| End Cash Position | 65,226 | 71,194 | 74,876 | 79,636 | 84,070 |
| Net Cash Flow | $-5,968 | $-17,376 | $-13,694 | $-8,934 | $-4,500 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,959 | -21,030 | -13,979 | -9,229 | -4,698 |
| Capital Expenditure | -9 | -19 | -19 | -9 | -6 |
| Free Cash Flow | -5,968 | -21,049 | -13,998 | -9,238 | -4,704 |